$64.43
0.12% today
Nasdaq, Sep 23, 07:48 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$64.51
+7.03 12.23% 1M
+11.98 22.81% 6M
+25.91 67.12% YTD
+18.36 39.78% 1Y
+56.15 671.65% 3Y
+43.33 204.58% 5Y
+52.81 451.37% 10Y
+52.81 451.37% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
+2.31 3.71%

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$3.4b
Net debt
positive
Cash
$570.5m
Shares outstanding
62.1m
Valuation (TTM | estimate)
P/E
79.6 | negative
P/S
19.2 | 86.0
EV/Sales
16.5 | 73.8
EV/FCF
92.8
P/B
6.0
Financial Health
Equity Ratio
90.7%
Return on Equity
40.8%
ROCE
3.5%
ROIC
17.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$209.2m | $46.7m
EBITDA
$25.7m | $-146.1m
EBIT
$24.0m | $-148.3m
Net Income
$52.0m | $-125.4m
Free Cash Flow
$37.1m
Growth (TTM | estimate)
Revenue
-34.5% | -89.3%
EBITDA
-83.4% | -157.2%
EBIT
-84.3% | -158.7%
Net Income
-69.4% | -145.6%
Free Cash Flow
-83.9%
Margin (TTM | estimate)
Gross
-
EBITDA
12.3% | -313.1%
EBIT
11.5%
Net
24.9% | -268.6%
Free Cash Flow
17.7%
More
EPS
$0.8
FCF per Share
$0.6
Short interest
13.2%
Employees
126
Rev per Employee
$3.5m
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
209 209
34% 34%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
3% 3%
20%
- Research and Development Expense 144 144
13% 13%
69%
26 26
83% 83%
12%
- Depreciation and Amortization 1.73 1.73
21% 21%
1%
EBIT (Operating Income) EBIT 24 24
84% 84%
11%
Net Profit 52 52
69% 69%
25%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
13 days ago
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 11:30 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Douglas Tsao - H.C.
Neutral
Seeking Alpha
20 days ago
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Welcome to the second day of the Citi Biopharma Back to School Summit. I'm ...
Neutral
Accesswire
28 days ago
NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 126
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today